Bruker Corporation $BRKR is Sculptor Capital LP's 7th Largest Position

Key Points

• Sculptor Capital LP increased its stake in Bruker Corporation by 51.6%, acquiring a total of 2,598,438 shares, making Bruker its 7th largest holding with a value of approximately $108.5 million.
• Bruker reported $0.32 EPS for the last quarter, slightly below analysts' expectations, with revenue of $797.4 million and a guidance of $1.950-2.050 EPS for FY 2025.
• The company announced a quarterly dividend of $0.05 per share, with an annualized yield of 0.6%, set to be paid on October 3rd to shareholders on record by September 23rd.

Sculptor Capital LP increased its position in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 51.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,598,438 shares of the medical research company's stock after purchasing an additional 884,423 shares during the quarter. Bruker accounts for approximately 2.1% of Sculptor Capital LP's investment portfolio, making the stock its 7th largest holding. Sculptor Capital LP owned 1.71% of Bruker worth $108,459,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of BRKR. London Co. of Virginia raised its stake in shares of Bruker by 78.4% during the 4th quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock worth $245,820,000 after buying an additional 1,843,294 shares during the period. Steadfast Capital Management LP purchased a new stake in shares of Bruker during the fourth quarter worth approximately $63,997,000. Nuveen LLC purchased a new stake in Bruker in the 1st quarter valued at $20,764,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Bruker in the 1st quarter valued at $19,369,000. Finally, Brown Advisory Inc. grew its holdings in Bruker by 18.9% in the 1st quarter. Brown Advisory Inc. now owns 2,410,137 shares of the medical research company's stock valued at $100,599,000 after buying an additional 383,425 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bruker

In other news, CEO Frank H. Laukien purchased 2,608 shares of the stock in a transaction on Friday, June 6th. The stock was purchased at an average price of $38.36 per share, with a total value of $100,042.88. Following the completion of the transaction, the chief executive officer owned 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. The trade was a 0.01% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 27.30% of the company's stock.

Bruker Trading Down 11.7%

Bruker stock traded down $3.88 during trading on Wednesday, hitting $29.35. The company's stock had a trading volume of 18,320,680 shares, compared to its average volume of 2,534,366. The stock has a market capitalization of $4.45 billion, a price-to-earnings ratio of 56.44, a P/E/G ratio of 2.79 and a beta of 1.21. The stock's fifty day moving average is $37.82 and its 200 day moving average is $40.03. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $72.94. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business had revenue of $797.40 million during the quarter, compared to analyst estimates of $811.17 million. During the same quarter in the previous year, the company posted $0.52 earnings per share. The business's revenue for the quarter was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, equities research analysts predict that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Tuesday, September 23rd. Bruker's payout ratio is 38.46%.

Wall Street Analyst Weigh In

BRKR has been the topic of several recent analyst reports. Jefferies Financial Group set a $60.00 price target on Bruker and gave the company a "buy" rating in a research note on Monday, August 4th. Citigroup reduced their price target on Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a research report on Monday, August 4th. Wells Fargo & Company cut their target price on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 5th. Stifel Nicolaus set a $40.00 target price on Bruker and gave the stock a "hold" rating in a research report on Tuesday, August 5th. Finally, Bank of America dropped their price target on Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Five research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $51.30.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.